Last reviewed · How we verify
Rayaldee
At a glance
| Generic name | Rayaldee |
|---|---|
| Also known as | CTAP101 Capsule |
| Sponsor | OPKO Health, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vitamin D Status in Young Medical Residents
- Evaluation of Serum TRACP-5b, BALP, and 25-Hydroxyvitamin D3 Levels in Stage III Periodontitis Patients (NA)
- Effect of Vitamin D in Diets of Preterm Infants (NA)
- Effect of Vitamin D Deficiency on the Frequency and Severity of Spinal Anesthesia-Induced Hypotension in Pregnant Women Undergoing Cesarean Section
- Exercise Training and Vitamin D Metabolism (NA)
- Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics
- Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients (NA)
- Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rayaldee CI brief — competitive landscape report
- Rayaldee updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI